3d systems advances regenerative medical solutions for first-of-its-kind peripheral nerve repair

Collaboration with french medtech company, tissium, has resulted in fda approval for unique 3d-printed polymeric solution for repair of peripheral nerve damage 3d systems' bioprinting system enabled production of a 3d-printed bioabsorbable medical device leveraging tissium's proprietary biomorphic programable polymers—a major industry milestone that sets new standard for high resolution elastomeric 3d-printed medical implants builds on 3d systems' pioneering work to develop additive manufacturing solutions for regenerative medicine applications 3d systems' solutions accelerating additive manufacturing use in bioprinting—total market anticipated to reach more than $2 billion by end of 2029 rock hill, south carolina, june 26, 2025 (globe newswire) -- today, 3d systems (nyse: ddd) announced that its 3d bioprinting technologies have enabled fda approval for the regenerative repair of peripheral nerve damage. for the last several years, 3d systems has partnered with tissium, a french medtech company that is a pioneer in the development of biomorphic programmable polymers for tissue reconstruction, to develop a bespoke 3d printing solution for the repair of damaged peripheral nerves.
DDD Ratings Summary
DDD Quant Ranking